In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy organization, today announced the appointment of Amy Hajari Case, MD, FCCP, as ...

AN INSIGHTFUL session on the future of lung transplantation presented at this year’s European Respiratory Society (ERS) ...

Anti-fibrotic therapies, like Ofev and Genentech's Esbriet (pirfenidone), work by slowing the rate of fibrosis and are ...

GSK is pumping £50 million (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge ...

Sam Kirton started his column in November 2021 and writes from his home at Lake Anna, Virginia, where he lives with his wife Susan. His diagnosis at age 59 with idiopathic pulmonary fibrosis in ...

its experimental therapy for serious lung disease idiopathic pulmonary fibrosis (IPF). The study will use the e-ILD platform to process high-resolution chest computed tomography (HRCT) images ...

Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that ...

Sweden's Crown Princess Victoria joined Denmark's Queen Mary and Norway's Crown Princess Mette-Marit in Berlin ...

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis ...

Washington Research Foundation (WRF) has awarded $6 million in grant funding through a new program designed to support late-stage preclinical development and first-in-human clinical trials of novel ...